PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Celecoxib - Pain & inflammation - musculoskeletal
PAD Profile : Celecoxib - Pain & inflammation - musculoskeletal Important
Keywords :
COXIIs, Coxib, cyclo-oxygenase-2, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, PNMP
Brand Names Include :
Celebrex
Important Information :
Preferred COX II inhibitor for licensed indications
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Diclofenac sodium
- Diclofenac sodium
- Naproxen
- Etoricoxib
- Ibuprofen
- Naproxen
- Meloxicam
- Aceclofenac
- Diclofenac potassium
- Indometacin
- Nabumetone
- Etodolac
- Ketoprofen
- Mefenamic acid
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Surrey & North West Sussex Area Prescribing Committee recommends celecoxib as a treatment option for the treatment of pain and inflammation in line with the product licence*.
Celecoxib will be considered as GREEN on the traffic light system and is the preferred COX II inhibitor for use where a COX II inhibitor is indicated.
*Licenced for: Osteoarthritis, Rheumatoid Arthritis & Ankylosing Spondylitis
The branded product, Celebrex, is considered BLACK. Prescribe generically for this indication.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.01. Non-steroidal anti-inflammatory drugs